Milli-Mark® Anti-CD38-FITC Antibody, clone AT13/5

Description

• General description: CD38 is a 45 kDa type II integral membrane glycoprotein consisting of an N-terminal 20 amino acid cytoplasmic domain, a 23 amino acid transmembrane domain, and a 257 amino acid extracellular domain. CD38 is associated with different molecules in different cell types and these unique combinations cause unique cell-type specific signaling. One of the known ligands that activates CD38-mediated signaling is CD31 (Deaglio, 2001). CD38 is expressed by a number of different cell types and the pattern of expression often changes with differentiation and maturation. Thus, CD38 expression is found during early stages of B and T-cell differentiation, is lacking during the later intermediate stages, and is regained near the end of maturation. CD38 is expressed at variable levels on the majority of hematopoietic cells, prevalently during early differentiation and activation, and it is expressed strongly on plasma cells (Jackson, 1990; Terstappen, 1990; Morra, 1997). CD38-postive cell types outside the hematopoietic system include subsets from the gut, brain, prostate, pancreas, bone, eye, and muscle (Deaglio, 2001). CD38 is expressed on approximately 60% of CD34-positive peripheral blood mononuclear cells. The least mature CD34-postive cells are characterized by a lack of CD38 (Herbein, 1994). Anti-CD38, AT13/5 was included in the Sixth International Workshop and Conference on Human Leucocyte Differentiation Antigens, and studies by a number of laboratories confirmed its reactivity with CD38 (Morra, 1997).
• Specificity: Antibody recognizes Human CD38 antigen.
• Immunogen: Namalwa cells (B lymphocyte cell line from Burkitt′s lymphoma)
• Application: Milli-Mark Anti-CD38-FITC Antibody, clone AT13/5 is an antibody against CD38 for use in FC.
• Quality: Evaluated by flow cytometry using human lymphocytes
• Target description: 45 kDa (Deaglio, 2001)
• Physical form: Protein A purified
• Storage and Stability: Maintain refrigerated at 2-8°C protected from light in undiluted aliquots for up to 6 months from date of receipt.
• Analysis Note: ControlHuman Lymphocytes
• Legal Information: MILLI-MARK is a registered trademark of Merck KGaA, Darmstadt, Germany
• Disclaimer: Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.